emerg
virus
difficult
control
period
cycl
human
livestock
therefor
effect
vaccin
antivir
urgent
need
coronavirus
cov
repres
group
envelop
positivesens
singlestrand
virus
larg
genom
kb
capabl
caus
respiratori
enter
hepat
neurolog
diseas
differ
sever
divers
anim
speci
includ
human
cov
similar
genom
organ
approxim
twothird
genom
contain
replicas
gene
remaind
encod
spike
envelop
membran
nucleocapsid
structur
protein
along
sever
accessori
protein
cov
belong
famili
coronavirida
order
nidoviral
divid
four
genera
alpha
beta
gamma
deltacov
alpha
betacov
infect
human
four
cov
current
known
preval
human
cov
sever
acut
respiratori
syndrom
cov
sarscov
middl
east
respiratori
syndrom
cov
merscov
consid
emerg
cov
cov
infect
difficult
prevent
cure
although
cov
replic
machineri
exhibit
substanti
proofread
activ
estim
nucleotid
mutat
rate
cov
moder
high
rel
singlestrand
rna
virus
addit
larg
rna
genom
cov
allow
extra
plastic
genom
modif
recombin
moreov
mani
anim
cov
caus
longterm
persist
enzoot
infect
increas
probabl
infect
new
host
speci
sarscov
merscov
recent
exampl
newli
emerg
cov
caus
sever
human
diseas
sever
drug
ribavirin
lopinavirritonavir
interferon
corticosteroid
use
treat
patient
infect
sarscov
merscov
howev
contradictori
find
efficaci
concern
toler
clinic
benefit
limit
use
antivir
therapeut
cov
although
substanti
effort
focus
identifi
antivir
cov
treatment
approv
therapeut
drug
biolog
agent
current
avail
prophylaxi
treatment
covrel
diseas
treatment
emerg
cov
diseas
reli
upon
support
care
judici
use
limit
quantiti
experiment
therapeut
moreov
lack
effect
drug
high
morbid
mortal
rate
caus
viru
potenti
epidem
spread
highlight
need
new
broadspectrum
anticov
drug
especi
given
likelihood
infect
novel
cov
sever
recent
studi
highlight
potenti
broadspectrum
inhibitor
cov
de
wild
et
al
identifi
numer
potent
merscov
inhibitor
screen
us
food
drug
administr
fda
approv
drug
librari
interestingli
screen
compound
also
capabl
inhibit
replic
sarscov
dyall
et
al
also
screen
compound
activ
merscov
sarscov
librari
howev
halfmaxim
effect
concentr
valu
drug
rel
high
vitro
assess
vivo
make
clinic
util
question
et
al
found
silvestrol
potent
nontox
inhibitor
capdepend
viral
mrna
translat
covinfect
human
primari
cell
valu
nm
nm
merscov
respect
notabl
sheahan
et
al
show
nucleotid
prodrug
could
inhibit
sarscov
merscov
replic
multipl
vitro
system
submicromolar
halfmaxim
inhibitori
concentr
valu
furthermor
prophylact
earli
therapeut
administr
significantli
reduc
lung
viral
load
improv
clinic
sign
diseas
well
respiratori
function
mous
model
sarscov
pathogenesi
support
develop
broadspectrum
therapeut
protect
cov
sarscov
merscov
belong
betacov
show
high
degre
conserv
essenti
function
domain
especi
within
rdrp
rna
helicas
might
repres
potenti
target
broadspectrum
anticov
drug
recent
report
genet
engin
cov
strain
express
renilla
luciferas
rluc
facilit
highthroughput
screen
ht
broadspectrum
anticov
agent
quantit
analysi
cov
replic
present
studi
perform
ht
librari
contain
fdaapprov
drug
pharmacolog
activ
compound
assess
broadspectrum
anticov
activ
vitro
vivo
experiment
infect
mous
model
comprehens
screen
assess
provid
new
candid
inhibitor
effect
treat
infect
exist
cov
well
emerg
strain
futur
optim
screen
condit
establish
use
report
viru
infect
cell
plate
multipl
infect
moi
cellswel
condit
coeffici
variat
z
factor
respect
demonstr
assay
robust
suitabl
ht
schemat
ht
strategi
depict
fig
primari
screen
librari
concentr
hit
found
significantli
inhibit
replic
fig
red
yellow
squar
reduc
rluc
activ
cytotox
includ
fdaapprov
drug
obtain
potent
inhibitor
exclud
possibl
observ
antivir
activ
specif
confirm
antivir
activ
hit
wildtyp
quantit
revers
transcript
qrt
pcr
lower
concentr
confirm
antivir
activ
compound
fig
yellow
squar
alpha
betacov
infect
human
focus
three
cov
merscov
betacov
mous
hepat
viru
betacov
alphacov
assess
broadspectrum
antivir
activ
compound
use
eightpoint
doserespons
confirm
identifi
compound
inhibit
replic
alphacov
usual
caus
common
cold
wherea
compound
inhibit
merscov
replic
respect
tabl
moreov
newli
identifi
nine
compound
phenazopyridin
lycorin
pyrvinium
pamoat
monensin
sodium
cetylpyridinium
chlorid
oligomycin
loperamid
harmin
conessin
exhibit
antivir
activ
sever
cov
merscov
tabl
interestingli
follow
seven
compound
inhibit
replic
cov
valu
lycorin
emetin
phenazopyridin
mycophenol
acid
mycophenol
mofetil
pyrvinium
pamoat
monensin
sodium
tabl
compound
indic
bold
seven
broadspectrum
inhibitor
suppress
replic
cov
dosedepend
manner
low
valu
fig
lycorin
activ
alkaloid
common
folk
medicin
lycori
radiata
amaryllidacea
investig
multifunct
biolog
effect
includ
anticanc
antimalari
antivir
antibacteri
antiinflammatori
activ
lycorin
show
potent
anticov
activ
valu
rang
moreov
select
index
si
lycorin
calcul
indic
potent
activ
fig
emetin
activ
princip
ipecac
inhibit
replic
dna
rna
virus
addit
emetin
display
potent
anticov
activ
strongest
antimerscov
activ
among
top
seven
inhibitor
valu
si
fig
mycophenol
acid
immunosuppress
exert
signific
inhibitori
effect
replic
show
stronger
activ
other
si
fig
mycophenol
mofetil
deriv
mycophenol
acid
show
antivir
effect
four
cov
similar
mycophenol
acid
suggest
two
drug
might
harbor
similar
core
structur
antivir
mechan
fig
e
moreov
phenazopyridin
wide
use
urinari
analges
also
display
strong
broadspectrum
anticov
activ
first
time
especi
si
fig
pyrvinium
pamoat
fdaapprov
anthelminth
drug
potent
inhibitor
wnt
signal
suggest
occur
direct
activ
protein
kinas
pyrvinium
pamoat
inhibit
replic
cov
display
low
toxic
cytotox
concentr
fig
final
monensin
sodium
previous
shown
inhibit
format
gammacov
infecti
bronchiti
viru
ibv
inhibit
cov
low
valu
display
low
toxic
fig
although
specif
antivir
mechan
seven
inhibitor
cov
unknown
show
potenti
new
antivir
treatment
infect
caus
rang
cov
verifi
antivir
activ
seven
inhibitor
indirect
immunofluoresc
assay
ifa
western
blot
analysi
shown
fig
seven
inhibitor
significantli
suppress
replic
compar
control
dimethyl
sulfoxid
dmso
inhibitori
effect
compound
except
monensin
sodium
addit
observ
inhibitori
activ
cell
treat
inhibitor
viral
infect
result
significantli
reduc
level
nucleocapsid
protein
fig
although
inhibitori
effect
mycophenol
acid
differ
accord
ifa
western
blot
result
seven
inhibitor
clearli
suppress
replic
viral
entri
essenti
step
viral
life
cycl
thu
attract
target
therapi
inhibit
step
block
viral
propag
earli
stage
infect
therebi
minim
chanc
viru
evolv
acquir
drug
resist
therefor
test
effect
seven
screen
inhibitor
cov
entri
use
pseudotyp
viru
human
immunodefici
viru
type
backbon
express
spike
protein
merscov
order
gener
doserespons
curv
measur
inhibit
percentag
show
emetin
entri
inhibitor
block
merscov
smediat
infect
luciferas
activ
reduc
compar
control
valu
fig
infect
neuron
caus
enceph
mice
model
previous
use
anticov
drug
evalu
moreov
model
conveni
base
lack
need
three
biolog
facil
contrast
experi
involv
sarscov
merscov
therefor
use
model
evalu
vivo
antivir
activ
seven
inhibitor
intracerebr
intranas
inocul
result
acuteonset
sever
neurolog
ill
caus
death
high
level
viral
replic
brain
titer
tissu
cultur
infect
dose
ml
day
infect
briefli
femal
balbc
mice
day
old
inocul
via
intranas
rout
treat
seven
inhibitor
day
surviv
monitor
day
inhibitor
dose
regimen
select
base
acutetox
assess
emetin
use
mgkg
chloroquin
use
posit
control
show
antivir
activ
mgkg
mice
phosphatebuff
salin
pb
dmsotreat
group
die
within
day
challeng
fig
contrast
mice
lycorinetr
group
still
aliv
day
postinocul
p
similar
surviv
rate
chloroquinetr
group
fig
addit
viral
load
brain
spinal
cord
limit
detect
lycorinetr
group
fig
immunohistochemistri
ihc
mous
brain
coron
section
show
nucleocapsid
protein
present
pbsdmsotreat
group
lycorinetr
group
fig
close
monitor
effect
lycorin
spread
replic
mous
central
nervou
system
real
time
use
bioluminesc
imag
bli
base
import
advantag
intrins
low
background
signal
high
sensit
monitor
light
emiss
vivo
expect
pbsdmsotreat
mice
show
gradual
increas
signal
intens
postinocul
wherea
signal
detect
brain
lycorinetr
mice
fig
observ
confirm
rluc
activ
pbsdmsotreat
mice
lycorinetr
mice
therefor
lycorin
show
promis
anticov
agent
fig
sar
epidem
ongo
merscov
outbreak
highlight
inadequaci
avail
treatment
lifethreaten
zoonot
cov
infect
human
inde
specif
antivir
agent
vaccin
current
avail
human
zoonot
cov
infect
despit
extens
research
effort
trigger
sar
outbreak
sever
fdaapprov
drug
ritonavir
lopinavir
nelfinavir
mycophenol
acid
ribavirin
inhibit
entri
andor
replic
merscov
sarscov
human
cov
multipl
cell
line
howev
antivir
efficaci
vivo
remain
unknown
date
small
molecul
demonstr
anticov
activ
anim
model
cov
infect
avail
anticov
drug
target
structur
protein
might
effect
cov
exampl
human
monoclon
antibodi
antivir
peptid
block
virushost
cell
bind
typic
limit
breadth
protect
due
antigen
divers
cov
spike
glycoprotein
worth
mention
combin
antivir
peptid
beta
interferon
combin
therapi
differ
human
human
monoclon
antibodi
target
noncrossresist
epitop
enhanc
antivir
therapeut
effect
also
sever
report
enhanc
therapeut
effect
combin
antivir
agent
treatment
merscov
result
indic
combin
use
differ
antivir
agent
might
synergist
treatment
cov
infect
identifi
seven
potent
broadspectrum
anticov
agent
among
lycorin
confirm
show
strong
anticov
activ
vivo
result
suggest
fdaapprov
drug
use
prophylaxi
sever
lethal
cov
infect
therebi
greatli
facilit
rapid
ration
develop
anticov
agent
desir
pharmacokinet
biodistribut
properti
criteria
inhibit
rate
associ
signal
antivir
ht
assay
rang
accord
differ
refer
primari
hit
fewer
efficaci
hit
screen
inhibit
rate
set
lower
threshold
experi
focus
screen
hit
higher
potenc
therefor
establish
inhibit
threshold
furthermor
identifi
sever
effect
hit
high
degre
cytotox
primari
screen
cytotox
valu
set
final
identifi
compound
exhibit
activ
librari
compound
two
chloroquin
loperamid
previous
report
exhibit
broadspectrum
anticov
activ
nine
compound
phenazopyridin
lycorin
pyrvinium
pamoat
monensin
sodium
cetylpyridinium
chlorid
oligomycin
loperamid
harmin
conessin
previous
demonstr
exhibit
antivir
activ
merscov
therebi
offer
new
therapeut
possibl
sever
cov
furthermor
seven
compound
lycorin
emetin
monensin
sodium
mycophenol
mofetil
mycophenol
acid
phenazopyridin
pyrvinium
pamoat
show
inhibitori
activ
multipl
genet
distinct
cov
vitro
lowmicromolar
concentr
valu
rang
among
lycorin
alkaloid
isol
amaryllidacea
plant
reportedli
exhibit
anticanc
antiplasmodi
antitrypanosom
antiinflammatori
analges
emet
activ
lycorin
inhibit
replic
poliomyel
viru
herp
simplex
viru
bunyamwera
viru
west
nile
viru
dengu
viru
sarscov
vitro
although
mechan
remain
elucid
liu
et
al
demonstr
abil
lycorin
reduc
mortal
human
enteroviru
mice
inhibit
viral
replic
furthermor
guo
et
al
evalu
total
lycorin
deriv
demonstr
suppress
enteroviru
hepat
c
viru
replic
variou
cell
moreov
drug
resist
analysi
reveal
target
phenylalanin
viral
proteas
lycorin
also
exhibit
strong
activ
influenza
viru
vitro
delay
export
nucleoprotein
nucleu
cytoplasm
replic
howev
potenti
mechan
lycorin
cov
requir
explor
potenti
select
drugresist
strain
must
assess
found
report
concern
whether
use
combin
enhanc
antivir
efficaci
lycorin
addit
emetin
drug
use
mainli
antiprotozo
emet
number
group
recent
report
new
antivir
role
emetin
emetin
reportedli
potent
inhibitor
suppress
replic
sever
rna
virus
dengu
viru
hiv
without
gener
drugresist
variant
virus
note
emetin
inhibit
human
cytomegaloviru
hcmv
replic
disrupt
hcmvinduc
interact
ligas
moreov
recent
studi
reveal
emetin
inhibitori
modul
rabi
viru
axon
transport
via
mechan
independ
protein
synthesi
inhibit
furthermor
yang
et
al
demonstr
emetin
inhibit
zika
viru
zikv
replic
via
inhibit
zikv
polymeras
activ
disrupt
lysosom
function
present
studi
preliminari
result
indic
emetin
inhibit
merscov
entri
interestingli
immunosuppress
mycophenol
acid
deriv
mycophenol
mofetil
suppress
merscov
replic
also
inhibit
replic
valu
respect
howev
previou
studi
show
merscovinfect
common
marmoset
treat
mycophenol
mofetil
sever
form
diseas
higher
lung
viral
load
untreat
anim
renal
transplant
recipi
mainten
mycophenol
mofetil
therapi
reportedli
develop
sever
fatal
mer
therefor
two
inhibitor
unlik
use
cov
infect
monensin
sodium
affect
ibv
assembl
also
identifi
inhibitor
cov
merscov
studi
lycorin
show
strong
antivir
activ
multipl
genet
distinct
cov
vitro
protect
mice
lethal
infect
vivo
knowledg
first
report
use
bli
evalu
effect
antivir
agent
cov
replic
dissemin
vivo
without
need
anim
quantifi
viral
titer
establish
complet
pattern
viru
dissemin
central
nervou
system
howev
data
conclus
concern
antivir
effect
inhibitor
deriv
one
cell
line
test
differ
cov
replic
cell
line
order
exclud
influenc
host
cell
factor
especi
merscov
larger
number
suscept
cell
line
eg
huh
cell
therefor
vitro
vivo
studi
warrant
determin
potenti
antivir
mechan
associ
seven
compound
well
clinic
efficaci
addit
efficaci
lycorineinterferon
combin
explor
anim
model
follow
sar
mer
futur
emerg
cov
like
pose
threat
public
health
therefor
identif
broadspectrum
inhibitor
sarscov
merscov
futur
emerg
cov
research
prioriti
perspect
potent
broadspectrum
inhibitor
lycorin
emetin
identifi
studi
might
effect
cov
infect
either
singl
agent
combin
dbt
cell
cell
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
thermo
fisher
scientif
waltham
usa
supplement
fetal
bovin
serum
fb
gibco
incub
atmospher
contain
genbank
access
number
express
rluc
gene
deriv
infecti
cdna
clone
use
ht
cell
strain
amsterdam
use
infect
monolay
cell
moi
merscov
strain
emc
use
infect
monolay
cell
moi
mhv
strain
propag
cell
plaqu
assay
perform
monolay
dbt
cell
infect
mhv
moi
librari
contain
fdaapprov
drug
pharmacolog
activ
compound
purchas
microsourc
discoveri
system
inc
gaylordsvil
ct
usa
see
tabl
supplement
materi
nucleocapsid
protein
mous
monoclon
antibodi
made
inhous
rabbit
monoclon
antibodi
obtain
cell
signal
technolog
danver
usa
infrar
irdy
goat
antimous
igg
goat
antirabbit
igg
purchas
licor
bioscienc
lincoln
ne
usa
mhv
titer
quantifi
plaqu
assay
describ
previous
viral
genom
rna
merscov
extract
cell
cultur
supernat
use
qiaamp
viral
rna
minikit
qiagen
valencia
ca
usa
quantifi
realtim
rtpcr
describ
previous
primer
probe
sequenc
follow
cag
gaa
ggt
ctg
ctc
tgc
act
aga
ggc
tct
ttc
cag
atc
tac
ttc
gcg
cac
atc
ctamra
acc
tta
aat
tca
gac
aac
gtt
tac
gtt
tgc
gat
tac
caa
gac
cag
ttt
tag
cac
ctt
cct
tag
caa
ccc
aaa
qmersf
act
gag
gac
cca
cgt
qmersr
cga
cat
acc
cat
aaa
agc
qmersprob
caa
att
gct
gag
ctt
gct
cct
replic
effici
cell
cell
line
commonli
use
viru
isol
antivir
screen
assay
therefor
primari
screen
assay
conduct
use
compound
cell
observ
differ
averag
rluc
signal
mock
control
report
viru
ad
dmso
control
averag
control
mock
dmso
control
signal
luciferas
light
unit
background
cell
luciferas
light
unit
briefli
cell
seed
plate
dmem
supplement
fb
overnight
incub
atmospher
well
contain
cell
medium
replac
dmem
supplement
fb
compound
dilut
dmso
ad
plate
final
concentr
one
compound
per
well
triplic
equal
volum
dmso
alon
ad
dmso
control
well
fig
incub
min
dilut
viral
suspens
ad
well
moi
final
total
screen
volum
plate
incub
h
luciferas
activ
determin
use
renillaglo
luciferas
assay
system
promega
madison
wi
usa
accord
manufactur
instruct
antivir
activ
calcul
follow
inhibit
rluc
activ
rel
luminesc
unit
compoundtr
cellsrel
luminesc
unit
dmsotreat
control
cell
cytotox
calcul
follow
inhibit
prolifer
cell
viabil
compoundtr
cellscel
viabil
dmsotreat
control
cell
valu
compoundspecif
toxic
calcul
graphpad
prism
softwar
graphpad
inc
la
jolla
ca
usa
use
nonlinear
regress
model
z
factor
assess
qualiti
screen
assay
determin
compound
consid
effect
reduc
rluc
activ
cytotox
confirm
assay
perform
use
treat
compound
two
concentr
viral
rna
load
determin
qrtpcr
screen
hit
higher
potenc
narrow
screen
scope
compound
consid
effect
valu
cell
lyse
incub
buffer
min
lysat
separ
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
transfer
nitrocellulos
membran
block
skim
milk
pb
h
incub
primari
antibodi
overnight
wash
pb
plu
tween
buffer
membran
incub
h
appropri
secondari
antibodi
scan
use
odyssey
infrar
imag
system
licor
bioscienc
cell
plate
infect
moi
presenc
indic
inhibitor
chloroquin
dmso
use
posit
neg
control
respect
h
postinfect
cell
fix
formaldehyd
permeabil
triton
block
bovin
serum
albumin
pb
probe
primari
antibodi
nucleocapsid
protein
h
room
temperatur
cell
wash
three
time
pb
incub
fluorescein
isothiocyanatelabel
goat
antimous
igg
sigmaaldrich
st
loui
mo
usa
dilut
h
cell
wash
stain
dapi
invitrogen
carlsbad
ca
usa
detect
nuclei
fluoresc
imag
obtain
analyz
use
fluoresc
microscop
nikon
melvil
ny
usa
video
document
system
cell
viabil
assess
methylthiazolyltetrazolium
mtt
assay
h
mtt
ad
final
concentr
mgml
cell
incub
h
humidifi
incub
plate
centrifug
g
min
supernat
remov
well
aspir
micropipett
subsequ
dmso
ad
per
well
plate
gentli
shaken
absorb
nm
detect
use
microelisa
auto
reader
spectromet
dynatech
laboratori
inc
charlottesvil
va
usa
inhibitori
activ
select
inhibitor
cov
entri
determin
use
pseudovirus
describ
previous
briefli
cell
cotransfect
plasmid
pvrcmerss
cultur
supernat
contain
suffici
pseudotyp
merscov
collect
h
posttransfect
upon
reach
densiti
cellswel
plate
dipeptidyl
peptidas
express
cell
infect
pseudoviru
merscov
presenc
inhibitor
differ
concentr
cultur
medium
renew
fresh
medium
contain
fb
luciferas
activ
determin
addit
h
incub
use
promega
glomax
plate
luminomet
promega
twelvedayold
femal
balbc
mice
inocul
via
intranas
rout
h
mice
treat
test
compound
dmso
pb
buffer
anim
inject
intraperiton
daili
compound
emetin
use
mgkg
chloroquin
use
mgkg
inhibitor
use
mgkg
surviv
monitor
day
postinocul
procedur
involv
anim
perform
complianc
guid
care
use
laboratori
anim
peopl
republ
china
studi
protocol
approv
committe
ethic
anim
experi
chines
center
diseas
control
prevent
balbc
mice
infect
treat
lycorin
dmsopb
follow
immedi
anesthet
isofluran
intraperiton
administr
viviren
vivo
renilla
luciferas
substrat
promega
day
postinocul
mice
posit
special
design
box
place
onto
stage
insid
lighttight
camera
box
mice
imag
within
min
postinject
substrat
photon
flux
quantit
use
live
imag
softwar
perkinelm
waltham
usa
mous
brain
remov
day
postinfect
fix
formalin
tissu
process
ihc
describ
previous
differ
group
examin
statist
signific
use
student
test
p
consid
statist
signific
